endTB aims to find shorter, less toxic and more effective treatments for ‘multidrug-resistant TB’ (MDR-TB) through:

  • access to new drugs
  • two clinical trials
  • advocacy at national and global levels.

Covering 18 countries, the project is a partnership between Partners In Health, Médecins Sans Frontières, Interactive Research & Development and financial partners UNITAID and the Transformational Investment Capacity (TIC) of MSF. 

You can contact us, or follow us on Twitter.

Watch the two-minute animation

endTB clinical trial results - VIDEO

The endTB clinical trial results are out! This landmark trial offers multiple new shortened, all-oral drug regimens to treat adults and children with MDR-TB. 

Read our press release and more here: https://endtb.org/endtb-clinical-trial-results 

endTB trial results presentation at the Union World Conference

Union World Conference

October 02, 2023

The endTB trial results will be presented, for the first time, at the Union World Conference on Lung Health, in Paris, France, on November 15-18. 

Read more 

PIH MSF MSF Unitaid: Save Lives Faster Médecins Sans Frontières (MSF) Transformational Investment Capacity (TIC) logo